Osteonecrosis of the Jaw

Comprehensive Clinical Guide: Osteonecrosis of the Jaw (ONJ)

Osteonecrosis of the jaw (ONJ), specifically Medication-Related Osteonecrosis of the Jaw (MRONJ), represents one of the most challenging clinical entities in contemporary oral and maxillofacial surgery. It is characterized by the progressive destruction and death of bone tissue in the mandible or maxilla, resulting in exposed bone that fails to heal over an extended period.

1. Introduction and Clinical Overview

Osteonecrosis of the jaw is a severe adverse drug reaction or localized pathology where the blood supply to the bone is compromised, leading to cellular death and subsequent bone sequestration. While historically associated with radiation therapy (Osteoradionecrosis - ORN), the modern clinical landscape is dominated by MRONJ, linked primarily to antiresorptive and antiangiogenic medications.

The clinical hallmark is the presence of exposed bone in the maxillofacial region that persists for more than eight weeks in patients who have not received radiation therapy to the jaws. Because the jawbones have a high turnover rate and are subject to constant mechanical stress and microbial exposure from the oral cavity, they are uniquely susceptible to this necrotic process compared to other skeletal sites.

2. Etiology and Pathophysiology

The pathophysiology of ONJ is multifactorial, involving a complex interplay between bone remodeling suppression, angiogenesis inhibition, and local inflammatory/infectious triggers.

The Mechanism of Action

• Antiresorptive Agents: Bisphosphonates (e.g., zoledronic acid, alendronate) and RANK-ligand inhibitors (e.g., denosumab) are the primary culprits. They work by inhibiting osteoclast activity, effectively "freezing" bone turnover. While beneficial for preventing fractures in osteoporosis or oncology patients, this prevents the bone from repairing the micro-damage caused by daily masticatory forces.
• Antiangiogenic Agents: Medications like bevacizumab inhibit the vascular endothelial growth factor (VEGF), which is essential for blood vessel formation. Without adequate vascularization, the bone cannot maintain its viability or mount an immune response to oral bacteria.
• The "Double Hit" Hypothesis: The bone is already compromised by suppressed remodeling and poor vascularity. When an oral infection (periodontitis, periapical abscess) or mechanical trauma (tooth extraction) occurs, the bone lacks the regenerative capacity to heal, leading to localized necrosis.

3. Clinical Staging and Grading (AAOMS Criteria)

The American Association of Oral and Maxillofacial Surgeons (AAOMS) utilizes a staging system to guide clinical management.

• At-Risk Category: Patients treated with oral or IV antiresorptive/antiangiogenic agents with no evidence of necrotic bone.
• Stage 0: No clinical evidence of necrotic bone, but nonspecific clinical findings (e.g., odontalgia, loosening of teeth, sinus tract formation).
• Stage 1: Exposed, necrotic bone or fistulas in asymptomatic patients without infection.
• Stage 2: Exposed, necrotic bone or fistulas associated with infection (pain, purulent drainage, erythema).
• Stage 3: Exposed/necrotic bone extending beyond the alveolar bone (e.g., pathologic fracture, extraoral fistula, osteolysis extending to the inferior border of the mandible).

4. Differential Diagnosis

Distinguishing ONJ from other pathologies is critical, as misdiagnosis can lead to inappropriate surgical intervention, which may exacerbate the necrosis.

1. Osteoradionecrosis (ORN): Distinguished by a history of radiation therapy to the head and neck.
2. Chronic Osteomyelitis: Often presents with more aggressive signs of infection and systemic symptoms (fever, malaise).
3. Metastatic Malignancy: Bone metastasis (e.g., breast, prostate, or lung cancer) can mimic the radiographic appearance of ONJ. Biopsy is mandatory if the lesion does not respond to conservative therapy.
4. Periodontal Disease: Deep pockets and bone loss are common, but the exposed, necrotic bone characteristic of ONJ is absent.
5. Alveolar Osteitis (Dry Socket): Usually presents shortly after extraction and resolves with standard care; it does not result in long-term bone exposure.

5. Diagnostic Testing and Imaging

Clinical diagnosis is primary, but imaging is vital for assessing the extent of the disease.

• Clinical Examination: Probing of the site to identify necrotic bone (which feels hard and rough).
• Panoramic Radiography: Useful for initial screening to identify sclerotic bone, widened periodontal ligament spaces, or sequestration.
• Cone-Beam Computed Tomography (CBCT): The gold standard. It provides high-resolution, three-dimensional views of the bone architecture, allowing for the detection of early cortical changes, sequestra, and the involvement of the mandibular canal.
• Biopsy/Histopathology: Generally reserved for cases where malignancy is suspected or where the diagnosis is unclear.

6. Management and Prognosis

Management is generally conservative unless the disease is advanced.

Conservative Management

• Chlorhexidine Rinses: 0.12% oral rinses to reduce microbial load.
• Antibiotic Therapy: Targeted therapy (e.g., amoxicillin/clavulanate, clindamycin) for acute infections.
• Debridement: Removal of loose sequestra (small pieces of dead bone) under local anesthesia.

Surgical Management

• Resection: In Stage 3 cases (pathologic fracture or severe osteolysis), surgical resection of the necrotic bone and reconstruction with a bone graft or plate may be required.

Prognosis

The prognosis for ONJ is guarded. While early stages (1 and 2) can often be managed with long-term maintenance, Stage 3 disease carries a high morbidity rate. Prevention—specifically through dental clearance before starting antiresorptive therapy—remains the most effective tool in the clinical arsenal.

7. Risks and Contraindications

• Contraindicated Procedures: Elective dentoalveolar surgery (extractions, implants) should be avoided in patients currently receiving high-dose IV antiresorptives.
• Risk Factors:
  • Duration of therapy (the longer the exposure, the higher the risk).
  • Use of corticosteroids.
  • Poor oral hygiene.
  • Smoking.
  • Diabetes.

8. Frequently Asked Questions (FAQ)

1. Is ONJ reversible?

ONJ is generally considered a chronic condition. While it can be managed to prevent progression, the necrotic bone itself rarely "heals" in the traditional sense of regeneration.

2. Can I get a dental implant if I am on bisphosphonates?

This is controversial. Most specialists recommend avoiding elective implants for patients on high-dose IV bisphosphonates. For patients on low-dose oral therapy (e.g., for osteoporosis), the risk is lower, but informed consent is mandatory.

3. What is the difference between ORN and MRONJ?

ORN is caused by radiation-induced damage to the blood vessels and bone cells. MRONJ is caused by the suppression of bone remodeling and angiogenesis via medications.

4. How long do I need to stop my medication before surgery?

The concept of a "drug holiday" is debated. While some clinicians suggest stopping therapy for 2-3 months before and after surgery, there is no definitive consensus that this reduces the risk of ONJ.

5. Why does ONJ only affect the jaw?

The jaw has a higher turnover rate than other bones and is constantly exposed to the unique microbiome of the oral cavity, making it more susceptible to localized trauma and infection.

6. Is pain a constant symptom of ONJ?

No. Stage 1 ONJ is often asymptomatic. Pain usually indicates that the bone has become infected (Stage 2).

7. Does poor oral hygiene cause ONJ?

Poor hygiene is a significant risk factor because it increases the likelihood of dental infections, which act as a trigger for the necrotic process.

8. Are there any blood tests to predict ONJ?

Currently, there is no reliable serum biomarker (like C-terminal telopeptide) that accurately predicts an individual's risk of developing ONJ.

9. What should I do if I notice exposed bone in my mouth?

Contact an oral and maxillofacial surgeon immediately. Do not attempt to remove the bone fragment yourself, as this can lead to further trauma and infection.

10. Can ONJ be fatal?

ONJ itself is rarely fatal. However, the complications associated with advanced stages (e.g., secondary infection, airway obstruction, or the need for major reconstructive surgery) can have serious systemic consequences.

Conclusion

Osteonecrosis of the jaw is a complex, multifactorial condition that requires a multidisciplinary approach involving oncologists, endocrinologists, dentists, and oral surgeons. By focusing on preventive dental care, patient education, and early recognition of clinical signs, clinicians can significantly mitigate the impact of this condition on patient quality of life. The clinical focus must remain on conservative management of the exposed bone while maintaining an aggressive approach to oral health to prevent the triggers that lead to bone necrosis.